An investigation on behalf of investors in bluebird bio Inc (NASDAQ:BLUE) shares over potential wrongdoing at bluebird bio Inc was announced.
San Diego, CA -- (SBWIRE) -- 12/24/2018 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at bluebird bio.
Investors who purchased shares of bluebird bio Inc (NASDAQ:BLUE) and currently hold any of those NASDAQ:BLUE shares have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain bluebird bio directors breached their fiduciary duties and caused damage to the company and its shareholders.
On December 1, 2018, bluebird advised investors that it had "announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent ?-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH)."
On December 3, 2018, an article was published noting that these "results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin."
Those who purchased shares of bluebird bio Inc (NASDAQ:BLUE) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels